PONTE VEDRA, Fla., June 24, 2026
Cadrenal Therapeutics, Inc. announced that late-breaking clinical data from its Phase 2 study evaluating CAD-1005, a first-in-class 12-lipoxygenase (12-LOX) inhibitor, has been selected for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2026. The presentation will take place on July 12, 2026, during the Late-Breakthrough Abstracts session in Paris, highlighting the growing scientific interest in the company’s investigational therapy for Heparin-Induced Thrombocytopenia (HIT).
First Randomized Placebo-Controlled Trial Targets the Root Cause of HIT
The Phase 2 study represents the first randomized, blinded, placebo-controlled clinical trial conducted in patients with HIT, a life-threatening immune-mediated blood clotting disorder caused by antibodies that activate platelets following exposure to heparin. Unlike current treatment strategies that rely on non-heparin anticoagulants to reduce clot formation, CAD-1005 is designed to selectively inhibit 12-LOX, an enzyme involved in immune-mediated platelet activation and thrombo-inflammatory signaling. By targeting the biological mechanism responsible for disease progression, the therapy has the potential to introduce a fundamentally new treatment approach for acute thrombotic care.
Phase 3-Ready Program Targets Significant Unmet Medical Need
Cadrenal noted that CAD-1005 is Phase 3-ready and addresses an estimated peak annual market opportunity of approximately $2 billion for HIT. The investigational therapy has already received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, along with Orphan Drug status from the European Medicines Agency. Company executives believe the ISTH presentation provides an important opportunity to showcase the therapy’s clinical potential before a global audience of thrombosis specialists, clinicians, and researchers.
Advertisement
Cadrenal Expands Pipeline in Immune and Thrombotic Diseases
Beyond CAD-1005, Cadrenal Therapeutics continues to advance a broader pipeline focused on life-threatening immune and thrombotic disorders. The company’s portfolio also includes tecarfarin, a late-stage oral vitamin K antagonist being developed for patients requiring chronic anticoagulation, including those with end-stage kidney disease, left ventricular assist devices, and other high-risk cardiovascular conditions. With CAD-1005 progressing toward Phase 3 development, Cadrenal aims to establish a novel therapeutic option that addresses the underlying immune mechanisms driving HIT while strengthening its position in the thrombosis treatment landscape.
Source: Cadrenal Therapeutics press release
